APO Research
Talk to an analyst

APO RESEARCH · REPORT

Osteoarthritis Pain Drugs

The main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis, osteoarthritis in the use of two kinds of painkillers.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis, osteoarthritis in the use of two kinds of painkillers.

Selected research

Market Analysis & Forecast

Global Osteoarthritis Pain Drugs Market Analysis and Forecast 2026-2032

2 January 2026212 pages

Choose your research edition.

Industry ResearchOsteoarthritis Pain Drugs Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Osteoarthritis Pain Drugs Industry Growth and Trends Forecast to 2032128 pages · $3,450 USDMarket StructureGlobal Osteoarthritis Pain Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Osteoarthritis Pain Drugs Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Osteoarthritis Pain Drugs Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis, osteoarthritis in the use of two kinds of painkillers.

The major players in global Methylcyclohexane market include Pfizer, Johnson & Johnson, GlaxoSmithKline, etc. The top 3 players occupy about 45% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Oral is the main type, with a share over 50%. Personal Care is the main application, which holds a share about 90%.

This report presents an overview of global market for Osteoarthritis Pain Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

Read the full market overview

This report researches the key producers of Osteoarthritis Pain Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Osteoarthritis Pain Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Osteoarthritis Pain Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Osteoarthritis Pain Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Osteoarthritis Pain Drugs sales, projected growth trends, production technology, application and end-user industry.

Osteoarthritis Pain Drugs Segment by Company

Pfizer

Bayer

SK Chemicals

GSK

Sanofi

Crystal Genomics

Johnson & Johnson

Sino Biopharmaceutical

Haohai Biological

Zhejiang Chengyi Pharmaceutical

Freda

Bright Future

Jingfeng Pharmaceutical

Chugai Pharmaceutical

Mikasa Seiyaku

Taisho Pharmaceutical

Seikagaku Corporation

GlaxoSmithKline

Eli Lilly

Novartis

Horizon Pharma

Abbott

Mylan

Daiichi Sankyo

TEVA

Almatica Pharma

Astellas Pharma

Tide Pharmaceutical

Iroko Pharmaceuticals

Hengrui Pharmaceutical

Osteoarthritis Pain Drugs Segment by Type

Oral

Injection

External

Osteoarthritis Pain Drugs Segment by Application

Medical Care

Personal Care

Osteoarthritis Pain Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Osteoarthritis Pain Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Osteoarthritis Pain Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Osteoarthritis Pain Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Osteoarthritis Pain Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Osteoarthritis Pain Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Osteoarthritis Pain Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Osteoarthritis Pain Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oral Major Manufacturers Table 3. Injection Major Manufacturers Table 4. External Major Manufacturers Table 5. Global Osteoarthritis Pain Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Medical Care Major Manufacturers Table 7. Personal Care Major Manufacturers Table 8. Osteoarthritis Pain Drugs Industry Trends Table 9. Osteoarthritis Pain Drugs Industry Drivers Table 10. Osteoarthritis Pain Drugs Industry Opportunities and Challenges Table 11. Osteoarthritis Pain Drugs Industry Restraints Table 12. Global Osteoarthritis Pain Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Osteoarthritis Pain Drugs Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Osteoarthritis Pain Drugs Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Osteoarthritis Pain Drugs Revenue Market Share by Region (2021-2026) Table 16. Global Osteoarthritis Pain Drugs Revenue Market Share by Region (2027-2032) Table 17. Global Osteoarthritis Pain Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (M Dose) Table 18. Global Osteoarthritis Pain Drugs Sales by Region (2021-2026) & (M Dose) Table 19. Global Osteoarthritis Pain Drugs Sales by Region (2027-2032) & (M Dose) Table 20. Global Osteoarthritis Pain Drugs Sales Market Share by Region (2021-2026) Table 21. Global Osteoarthritis Pain Drugs Sales Market Share by Region (2027-2032) Table 22. Global Osteoarthritis Pain Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Osteoarthritis Pain Drugs Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Osteoarthritis Pain Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Osteoarthritis Pain Drugs Sales Market Share by Manufacturers (2021-2026) Table 26. Global Osteoarthritis Pain Drugs Sales Price (US$/Dose) of Manufacturers (2021-2026) Table 27. Global Osteoarthritis Pain Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Osteoarthritis Pain Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Osteoarthritis Pain Drugs Manufacturers, Product Type & Application Table 30. Global Osteoarthritis Pain Drugs Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Osteoarthritis Pain Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Osteoarthritis Pain Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Osteoarthritis Pain Drugs Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Osteoarthritis Pain Drugs Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Osteoarthritis Pain Drugs Revenue Market Share by Type (2021-2026) Table 37. Global Osteoarthritis Pain Drugs Revenue Market Share by Type (2027-2032) Table 38. Global Osteoarthritis Pain Drugs Sales by Type 2021 VS 2025 VS 2032 (M Dose) Table 39. Global Osteoarthritis Pain Drugs Sales by Type (2021-2026) & (M Dose) Table 40. Global Osteoarthritis Pain Drugs Sales by Type (2027-2032) & (M Dose) Table 41. Global Osteoarthritis Pain Drugs Sales Market Share by Type (2021-2026) Table 42. Global Osteoarthritis Pain Drugs Sales Market Share by Type (2027-2032) Table 43. Global Osteoarthritis Pain Drugs Price by Type (2021-2026) & (US$/Dose) Table 44. Global Osteoarthritis Pain Drugs Price by Type (2027-2032) & (US$/Dose) Table 45. Global Osteoarthritis Pain Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Osteoarthritis Pain Drugs Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Osteoarthritis Pain Drugs Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Osteoarthritis Pain Drugs Revenue Market Share by Application (2021-2026) Table 49. Global Osteoarthritis Pain Drugs Revenue Market Share by Application (2027-2032) Table 50. Global Osteoarthritis Pain Drugs Sales by Application 2021 VS 2025 VS 2032 (M Dose) Table 51. Global Osteoarthritis Pain Drugs Sales by Application (2021-2026) & (M Dose) Table 52. Global Osteoarthritis Pain Drugs Sales by Application (2027-2032) & (M Dose) Table 53. Global Osteoarthritis Pain Drugs Sales Market Share by Application (2021-2026) Table 54. Global Osteoarthritis Pain Drugs Sales Market Share by Application (2027-2032) Table 55. Global Osteoarthritis Pain Drugs Price by Application (2021-2026) & (US$/Dose) Table 56. Global Osteoarthritis Pain Drugs Price by Application (2027-2032) & (US$/Dose) Table 57. Pfizer Company Information Table 58. Pfizer Business Overview Table 59. Pfizer Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 60. Pfizer Osteoarthritis Pain Drugs Product Portfolio Table 61. Pfizer Recent Development Table 62. Bayer Company Information Table 63. Bayer Business Overview Table 64. Bayer Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 65. Bayer Osteoarthritis Pain Drugs Product Portfolio Table 66. Bayer Recent Development Table 67. SK Chemicals Company Information Table 68. SK Chemicals Business Overview Table 69. SK Chemicals Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 70. SK Chemicals Osteoarthritis Pain Drugs Product Portfolio Table 71. SK Chemicals Recent Development Table 72. GSK Company Information Table 73. GSK Business Overview Table 74. GSK Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 75. GSK Osteoarthritis Pain Drugs Product Portfolio Table 76. GSK Recent Development Table 77. Sanofi Company Information Table 78. Sanofi Business Overview Table 79. Sanofi Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 80. Sanofi Osteoarthritis Pain Drugs Product Portfolio Table 81. Sanofi Recent Development Table 82. Crystal Genomics Company Information Table 83. Crystal Genomics Business Overview Table 84. Crystal Genomics Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 85. Crystal Genomics Osteoarthritis Pain Drugs Product Portfolio Table 86. Crystal Genomics Recent Development Table 87. Johnson & Johnson Company Information Table 88. Johnson & Johnson Business Overview Table 89. Johnson & Johnson Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 90. Johnson & Johnson Osteoarthritis Pain Drugs Product Portfolio Table 91. Johnson & Johnson Recent Development Table 92. Sino Biopharmaceutical Company Information Table 93. Sino Biopharmaceutical Business Overview Table 94. Sino Biopharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 95. Sino Biopharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 96. Sino Biopharmaceutical Recent Development Table 97. Haohai Biological Company Information Table 98. Haohai Biological Business Overview Table 99. Haohai Biological Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 100. Haohai Biological Osteoarthritis Pain Drugs Product Portfolio Table 101. Haohai Biological Recent Development Table 102. Zhejiang Chengyi Pharmaceutical Company Information Table 103. Zhejiang Chengyi Pharmaceutical Business Overview Table 104. Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 105. Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 106. Zhejiang Chengyi Pharmaceutical Recent Development Table 107. Freda Company Information Table 108. Freda Business Overview Table 109. Freda Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 110. Freda Osteoarthritis Pain Drugs Product Portfolio Table 111. Freda Recent Development Table 112. Bright Future Company Information Table 113. Bright Future Business Overview Table 114. Bright Future Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 115. Bright Future Osteoarthritis Pain Drugs Product Portfolio Table 116. Bright Future Recent Development Table 117. Jingfeng Pharmaceutical Company Information Table 118. Jingfeng Pharmaceutical Business Overview Table 119. Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 120. Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 121. Jingfeng Pharmaceutical Recent Development Table 122. Chugai Pharmaceutical Company Information Table 123. Chugai Pharmaceutical Business Overview Table 124. Chugai Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 125. Chugai Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 126. Chugai Pharmaceutical Recent Development Table 127. Mikasa Seiyaku Company Information Table 128. Mikasa Seiyaku Business Overview Table 129. Mikasa Seiyaku Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 130. Mikasa Seiyaku Osteoarthritis Pain Drugs Product Portfolio Table 131. Mikasa Seiyaku Recent Development Table 132. Taisho Pharmaceutical Company Information Table 133. Taisho Pharmaceutical Business Overview Table 134. Taisho Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 135. Taisho Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 136. Taisho Pharmaceutical Recent Development Table 137. Seikagaku Corporation Company Information Table 138. Seikagaku Corporation Business Overview Table 139. Seikagaku Corporation Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 140. Seikagaku Corporation Osteoarthritis Pain Drugs Product Portfolio Table 141. Seikagaku Corporation Recent Development Table 142. GlaxoSmithKline Company Information Table 143. GlaxoSmithKline Business Overview Table 144. GlaxoSmithKline Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 145. GlaxoSmithKline Osteoarthritis Pain Drugs Product Portfolio Table 146. GlaxoSmithKline Recent Development Table 147. Eli Lilly Company Information Table 148. Eli Lilly Business Overview Table 149. Eli Lilly Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 150. Eli Lilly Osteoarthritis Pain Drugs Product Portfolio Table 151. Eli Lilly Recent Development Table 152. Novartis Company Information Table 153. Novartis Business Overview Table 154. Novartis Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 155. Novartis Osteoarthritis Pain Drugs Product Portfolio Table 156. Novartis Recent Development Table 157. Horizon Pharma Company Information Table 158. Horizon Pharma Business Overview Table 159. Horizon Pharma Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 160. Horizon Pharma Osteoarthritis Pain Drugs Product Portfolio Table 161. Horizon Pharma Recent Development Table 162. Abbott Company Information Table 163. Abbott Business Overview Table 164. Abbott Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 165. Abbott Osteoarthritis Pain Drugs Product Portfolio Table 166. Abbott Recent Development Table 167. Mylan Company Information Table 168. Mylan Business Overview Table 169. Mylan Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 170. Mylan Osteoarthritis Pain Drugs Product Portfolio Table 171. Mylan Recent Development Table 172. Daiichi Sankyo Company Information Table 173. Daiichi Sankyo Business Overview Table 174. Daiichi Sankyo Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 175. Daiichi Sankyo Osteoarthritis Pain Drugs Product Portfolio Table 176. Daiichi Sankyo Recent Development Table 177. TEVA Company Information Table 178. TEVA Business Overview Table 179. TEVA Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 180. TEVA Osteoarthritis Pain Drugs Product Portfolio Table 181. TEVA Recent Development Table 182. Almatica Pharma Company Information Table 183. Almatica Pharma Business Overview Table 184. Almatica Pharma Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 185. Almatica Pharma Osteoarthritis Pain Drugs Product Portfolio Table 186. Almatica Pharma Recent Development Table 187. Astellas Pharma Company Information Table 188. Astellas Pharma Business Overview Table 189. Astellas Pharma Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 190. Astellas Pharma Osteoarthritis Pain Drugs Product Portfolio Table 191. Astellas Pharma Recent Development Table 192. Tide Pharmaceutical Company Information Table 193. Tide Pharmaceutical Business Overview Table 194. Tide Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 195. Tide Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 196. Tide Pharmaceutical Recent Development Table 197. Iroko Pharmaceuticals Company Information Table 198. Iroko Pharmaceuticals Business Overview Table 199. Iroko Pharmaceuticals Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 200. Iroko Pharmaceuticals Osteoarthritis Pain Drugs Product Portfolio Table 201. Iroko Pharmaceuticals Recent Development Table 202. Hengrui Pharmaceutical Company Information Table 203. Hengrui Pharmaceutical Business Overview Table 204. Hengrui Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 205. Hengrui Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 206. Hengrui Pharmaceutical Recent Development Table 207. North America Osteoarthritis Pain Drugs Revenue by Type (2021-2026) & (US$ Million) Table 208. North America Osteoarthritis Pain Drugs Revenue by Type (2027-2032) & (US$ Million) Table 209. North America Osteoarthritis Pain Drugs Sales by Type (2021-2026) & (M Dose) Table 210. North America Osteoarthritis Pain Drugs Sales by Type (2027-2032) & (M Dose) Table 211. North America Osteoarthritis Pain Drugs Sales Price by Type (2021-2026) & (US$/Dose) Table 212. North America Osteoarthritis Pain Drugs Sales Price by Type (2027-2032) & (US$/Dose) Table 213. North America Osteoarthritis Pain Drugs Revenue by Application (2021-2026) & (US$ Million) Table 214. North America Osteoarthritis Pain Drugs Revenue by Application (2027-2032) & (US$ Million) Table 215. North America Osteoarthritis Pain Drugs Sales by Application (2021-2026) & (M Dose) Table 216. North America Osteoarthritis Pain Drugs Sales by Application (2027-2032) & (M Dose) Table 217. North America Osteoarthritis Pain Drugs Sales Price by Application (2021-2026) & (US$/Dose) Table 218. North America Osteoarthritis Pain Drugs Sales Price by Application (2027-2032) & (US$/Dose) Table 219. North America Osteoarthritis Pain Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 220. North America Osteoarthritis Pain Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 221. North America Osteoarthritis Pain Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 222. North America Osteoarthritis Pain Drugs Sales by Country (2021 VS 2025 VS 2032) & (M Dose) Table 223. North America Osteoarthritis Pain Drugs Sales by Country (2021-2026) & (M Dose) Table 224. North America Osteoarthritis Pain Drugs Sales by Country (2027-2032) & (M Dose) Table 225. North America Osteoarthritis Pain Drugs Sales Price by Country (2021-2026) & (US$/Dose) Table 226. North America Osteoarthritis Pain Drugs Sales Price by Country (2027-2032) & (US$/Dose) Table 227. United States Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 228. Canada Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 229. Mexico Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 230. Europe Osteoarthritis Pain Drugs Revenue by Type (2021-2026) & (US$ Million) Table 231. Europe Osteoarthritis Pain Drugs Revenue by Type (2027-2032) & (US$ Million) Table 232. Europe Osteoarthritis Pain Drugs Sales by Type (2021-2026) & (M Dose) Table 233. Europe Osteoarthritis Pain Drugs Sales by Type (2027-2032) & (M Dose) Table 234. Europe Osteoarthritis Pain Drugs Sales Price by Type (2021-2026) & (US$/Dose) Table 235. Europe Osteoarthritis Pain Drugs Sales Price by Type (2027-2032) & (US$/Dose) Table 236. Europe Osteoarthritis Pain Drugs Revenue by Application (2021-2026) & (US$ Million) Table 237. Europe Osteoarthritis Pain Drugs Revenue by Application (2027-2032) & (US$ Million) Table 238. Europe Osteoarthritis Pain Drugs Sales by Application (2021-2026) & (M Dose) Table 239. Europe Osteoarthritis Pain Drugs Sales by Application (2027-2032) & (M Dose) Table 240. Europe Osteoarthritis Pain Drugs Sales Price by Application (2021-2026) & (US$/Dose) Table 241. Europe Osteoarthritis Pain Drugs Sales Price by Application (2027-2032) & (US$/Dose) Table 242. Europe Osteoarthritis Pain Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 243. Europe Osteoarthritis Pain Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 244. Europe Osteoarthritis Pain Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 245. Europe Osteoarthritis Pain Drugs Sales by Country (2021 VS 2025 VS 2032) & (M Dose) Table 246. Europe Osteoarthritis Pain Drugs Sales by Country (2021-2026) & (M Dose) Table 247. Europe Osteoarthritis Pain Drugs Sales by Country (2027-2032) & (M Dose) Table 248. Europe Osteoarthritis Pain Drugs Sales Price by Country (2021-2026) & (US$/Dose) Table 249. Europe Osteoarthritis Pain Drugs Sales Price by Country (2027-2032) & (US$/Dose) Table 250. Germany Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 251. France Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 252. U.K. Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 253. Italy Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 254. Russia Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 255. Spain Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 256. Netherlands Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 257. Switzerland Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 258. Sweden Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 259. Poland Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 260. China Osteoarthritis Pain Drugs Revenue by Type (2021-2026) & (US$ Million) Table 261. China Osteoarthritis Pain Drugs Revenue by Type (2027-2032) & (US$ Million) Table 262. China Osteoarthritis Pain Drugs Sales by Type (2021-2026) & (M Dose) Table 263. China Osteoarthritis Pain Drugs Sales by Type (2027-2032) & (M Dose) Table 264. China Osteoarthritis Pain Drugs Sales Price by Type (2021-2026) & (US$/Dose) Table 265. China Osteoarthritis Pain Drugs Sales Price by Type (2027-2032) & (US$/Dose) Table 266. China Osteoarthritis Pain Drugs Revenue by Application (2021-2026) & (US$ Million) Table 267. China Osteoarthritis Pain Drugs Revenue by Application (2027-2032) & (US$ Million) Table 268. China Osteoarthritis Pain Drugs Sales by Application (2021-2026) & (M Dose) Table 269. China Osteoarthritis Pain Drugs Sales by Application (2027-2032) & (M Dose) Table 270. China Osteoarthritis Pain Drugs Sales Price by Application (2021-2026) & (US$/Dose) Table 271. China Osteoarthritis Pain Drugs Sales Price by Application (2027-2032) & (US$/Dose) Table 272. Asia Osteoarthritis Pain Drugs Revenue by Type (2021-2026) & (US$ Million) Table 273. Asia Osteoarthritis Pain Drugs Revenue by Type (2027-2032) & (US$ Million) Table 274. Asia Osteoarthritis Pain Drugs Sales by Type (2021-2026) & (M Dose) Table 275. Asia Osteoarthritis Pain Drugs Sales by Type (2027-2032) & (M Dose) Table 276. Asia Osteoarthritis Pain Drugs Sales Price by Type (2021-2026) & (US$/Dose) Table 277. Asia Osteoarthritis Pain Drugs Sales Price by Type (2027-2032) & (US$/Dose) Table 278. Asia Osteoarthritis Pain Drugs Revenue by Application (2021-2026) & (US$ Million) Table 279. Asia Osteoarthritis Pain Drugs Revenue by Application (2027-2032) & (US$ Million) Table 280. Asia Osteoarthritis Pain Drugs Sales by Application (2021-2026) & (M Dose) Table 281. Asia Osteoarthritis Pain Drugs Sales by Application (2027-2032) & (M Dose) Table 282. Asia Osteoarthritis Pain Drugs Sales Price by Application (2021-2026) & (US$/Dose) Table 283. Asia Osteoarthritis Pain Drugs Sales Price by Application (2027-2032) & (US$/Dose) Table 284. Asia Osteoarthritis Pain Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 285. Asia Osteoarthritis Pain Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 286. Asia Osteoarthritis Pain Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 287. Asia Osteoarthritis Pain Drugs Sales by Country (2021 VS 2025 VS 2032) & (M Dose) Table 288. Asia Osteoarthritis Pain Drugs Sales by Country (2021-2026) & (M Dose) Table 289. Asia Osteoarthritis Pain Drugs Sales by Country (2027-2032) & (M Dose) Table 290. Asia Osteoarthritis Pain Drugs Sales Price by Country (2021-2026) & (US$/Dose) Table 291. Asia Osteoarthritis Pain Drugs Sales Price by Country (2027-2032) & (US$/Dose) Table 292. Japan Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 293. South Korea Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 294. India Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 295. Australia Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 296. Taiwan Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 297. Southeast Asia Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 298. SAMEA Osteoarthritis Pain Drugs Revenue by Type (2021-2026) & (US$ Million) Table 299. SAMEA Osteoarthritis Pain Drugs Revenue by Type (2027-2032) & (US$ Million) Table 300. SAMEA Osteoarthritis Pain Drugs Sales by Type (2021-2026) & (M Dose) Table 301. SAMEA Osteoarthritis Pain Drugs Sales by Type (2027-2032) & (M Dose) Table 302. SAMEA Osteoarthritis Pain Drugs Sales Price by Type (2021-2026) & (US$/Dose) Table 303. SAMEA Osteoarthritis Pain Drugs Sales Price by Type (2027-2032) & (US$/Dose) Table 304. SAMEA Osteoarthritis Pain Drugs Revenue by Application (2021-2026) & (US$ Million) Table 305. SAMEA Osteoarthritis Pain Drugs Revenue by Application (2027-2032) & (US$ Million) Table 306. SAMEA Osteoarthritis Pain Drugs Sales by Application (2021-2026) & (M Dose) Table 307. SAMEA Osteoarthritis Pain Drugs Sales by Application (2027-2032) & (M Dose) Table 308. SAMEA Osteoarthritis Pain Drugs Sales Price by Application (2021-2026) & (US$/Dose) Table 309. SAMEA Osteoarthritis Pain Drugs Sales Price by Application (2027-2032) & (US$/Dose) Table 310. SAMEA Osteoarthritis Pain Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 311. SAMEA Osteoarthritis Pain Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 312. SAMEA Osteoarthritis Pain Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 313. SAMEA Osteoarthritis Pain Drugs Sales by Country (2021 VS 2025 VS 2032) & (M Dose) Table 314. SAMEA Osteoarthritis Pain Drugs Sales by Country (2021-2026) & (M Dose) Table 315. SAMEA Osteoarthritis Pain Drugs Sales by Country (2027-2032) & (M Dose) Table 316. SAMEA Osteoarthritis Pain Drugs Sales Price by Country (2021-2026) & (US$/Dose) Table 317. SAMEA Osteoarthritis Pain Drugs Sales Price by Country (2027-2032) & (US$/Dose) Table 318. Brazil Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 319. Argentina Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 320. Chile Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 321. Colombia Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 322. Peru Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 323. Saudi Arabia Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 324. Israel Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 325. UAE Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 326. Turkey Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 327. Iran Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 328. Egypt Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Table 329. Key Raw Materials Table 330. Raw Materials Key Suppliers Table 331. Osteoarthritis Pain Drugs Distributors List Table 332. Osteoarthritis Pain Drugs Customers List Table 333. Research Programs/Design for This Report Table 334. Authors List of This Report Table 335. Secondary Sources Table 336. Primary Sources List of Figures Figure 1. Osteoarthritis Pain Drugs Image Figure 2. Global Osteoarthritis Pain Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Osteoarthritis Pain Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oral Image Figure 5. Injection Image Figure 6. External Image Figure 7. Global Osteoarthritis Pain Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Osteoarthritis Pain Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Medical Care Image Figure 10. Personal Care Image Figure 11. Global Osteoarthritis Pain Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Osteoarthritis Pain Drugs Revenue (2021-2032) & (US$ Million) Figure 13. Global Osteoarthritis Pain Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Osteoarthritis Pain Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Osteoarthritis Pain Drugs Revenue Market Share by Region (2021-2032) Figure 16. Global Osteoarthritis Pain Drugs Sales (2021-2032) & (M Dose) Figure 17. Global Osteoarthritis Pain Drugs Sales by Region: 2021 VS 2025 VS 2032 (M Dose) Figure 18. Global Osteoarthritis Pain Drugs Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Osteoarthritis Pain Drugs Sales YoY (2021-2032) & (M Dose) Figure 20. Europe Osteoarthritis Pain Drugs Sales YoY (2021-2032) & (M Dose) Figure 21. China Osteoarthritis Pain Drugs Sales YoY (2021-2032) & (M Dose) Figure 22. Asia (Excluding China) Osteoarthritis Pain Drugs Sales YoY (2021-2032) & (M Dose) Figure 23. South America, Middle East and Africa Osteoarthritis Pain Drugs Sales YoY (2021-2032) & (M Dose) Figure 24. Global Osteoarthritis Pain Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Osteoarthritis Pain Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Osteoarthritis Pain Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Osteoarthritis Pain Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Osteoarthritis Pain Drugs Revenue Market Share by Type (2021-2032) Figure 30. Global Osteoarthritis Pain Drugs Sales by Type (2021 VS 2025 VS 2032) & (M Dose) Figure 31. Global Osteoarthritis Pain Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Osteoarthritis Pain Drugs Sales Market Share by Type (2021-2032) Figure 33. Global Osteoarthritis Pain Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Osteoarthritis Pain Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Osteoarthritis Pain Drugs Revenue Market Share by Application (2021-2032) Figure 36. Global Osteoarthritis Pain Drugs Sales by Application (2021 VS 2025 VS 2032) & (M Dose) Figure 37. Global Osteoarthritis Pain Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Osteoarthritis Pain Drugs Sales Market Share by Application (2021-2032) Figure 39. North America Osteoarthritis Pain Drugs Revenue Share by Type (2021-2032) Figure 40. North America Osteoarthritis Pain Drugs Sales Share by Type (2021-2032) Figure 41. North America Osteoarthritis Pain Drugs Revenue Share by Application (2021-2032) Figure 42. North America Osteoarthritis Pain Drugs Sales Share by Application (2021-2032) Figure 43. North America Osteoarthritis Pain Drugs Revenue Share by Country (2021-2032) Figure 44. North America Osteoarthritis Pain Drugs Sales Share by Country (2021-2032) Figure 45. Europe Osteoarthritis Pain Drugs Revenue Share by Type (2021-2032) Figure 46. Europe Osteoarthritis Pain Drugs Sales Share by Type (2021-2032) Figure 47. Europe Osteoarthritis Pain Drugs Revenue Share by Application (2021-2032) Figure 48. Europe Osteoarthritis Pain Drugs Sales Share by Application (2021-2032) Figure 49. Europe Osteoarthritis Pain Drugs Revenue Share by Country (2021-2032) Figure 50. Europe Osteoarthritis Pain Drugs Sales Share by Country (2021-2032) Figure 51. China Osteoarthritis Pain Drugs Revenue Share by Type (2021-2032) Figure 52. China Osteoarthritis Pain Drugs Sales Share by Type (2021-2032) Figure 53. China Osteoarthritis Pain Drugs Revenue Share by Application (2021-2032) Figure 54. China Osteoarthritis Pain Drugs Sales Share by Application (2021-2032) Figure 55. Asia Osteoarthritis Pain Drugs Revenue Share by Type (2021-2032) Figure 56. Asia Osteoarthritis Pain Drugs Sales Share by Type (2021-2032) Figure 57. Asia Osteoarthritis Pain Drugs Reven

Scope & coverage.

Types
  • Oral
  • Injection
  • External
Applications
  • Medical Care
  • Personal Care
Companies covered
  • Pfizer
  • Bayer
  • SK Chemicals
  • GSK
  • Sanofi
  • Crystal Genomics
  • Johnson & Johnson
  • Sino Biopharmaceutical
  • Haohai Biological
  • Zhejiang Chengyi Pharmaceutical
  • Freda
  • Bright Future
  • Jingfeng Pharmaceutical
  • Chugai Pharmaceutical
  • Mikasa Seiyaku
  • Taisho Pharmaceutical
  • Seikagaku Corporation
  • GlaxoSmithKline
  • Eli Lilly
  • Novartis
  • Horizon Pharma
  • Abbott
  • Mylan
  • Daiichi Sankyo
  • TEVA
  • Almatica Pharma
  • Astellas Pharma
  • Tide Pharmaceutical
  • Iroko Pharmaceuticals
  • Hengrui Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Osteoarthritis Pain Drugs Market by Type
  3. 1.2.1 Global Osteoarthritis Pain Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oral
  5. 1.2.3 Injection
  6. 1.2.4 External
  7. 1.3 Osteoarthritis Pain Drugs Market by Application
  8. 1.3.1 Global Osteoarthritis Pain Drugs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Medical Care
  10. 1.3.3 Personal Care
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Osteoarthritis Pain Drugs Market Dynamics
  1. 2.1 Osteoarthritis Pain Drugs Industry Trends
  2. 2.2 Osteoarthritis Pain Drugs Industry Drivers
  3. 2.3 Osteoarthritis Pain Drugs Industry Opportunities and Challenges
  4. 2.4 Osteoarthritis Pain Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Osteoarthritis Pain Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Osteoarthritis Pain Drugs Revenue by Region
  3. 3.2.1 Global Osteoarthritis Pain Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Osteoarthritis Pain Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Osteoarthritis Pain Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Osteoarthritis Pain Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Osteoarthritis Pain Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Osteoarthritis Pain Drugs Sales by Region
  9. 3.4.1 Global Osteoarthritis Pain Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Osteoarthritis Pain Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Osteoarthritis Pain Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Osteoarthritis Pain Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Osteoarthritis Pain Drugs Revenue by Manufacturers
  2. 4.1.1 Global Osteoarthritis Pain Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Osteoarthritis Pain Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Osteoarthritis Pain Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Osteoarthritis Pain Drugs Sales by Manufacturers
  6. 4.2.1 Global Osteoarthritis Pain Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Osteoarthritis Pain Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Osteoarthritis Pain Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Osteoarthritis Pain Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Osteoarthritis Pain Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Osteoarthritis Pain Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Osteoarthritis Pain Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Osteoarthritis Pain Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Osteoarthritis Pain Drugs Market CR5 and HHI
  16. 4.8.2 2025 Osteoarthritis Pain Drugs Tier 1, Tier 2, and Tier 3
5 Osteoarthritis Pain Drugs Market by Type
  1. 5.1 Global Osteoarthritis Pain Drugs Revenue by Type
  2. 5.1.1 Global Osteoarthritis Pain Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Osteoarthritis Pain Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Osteoarthritis Pain Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Osteoarthritis Pain Drugs Sales by Type
  6. 5.2.1 Global Osteoarthritis Pain Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Osteoarthritis Pain Drugs Sales by Type (2021-2032) & (M Dose)
  8. 5.2.3 Global Osteoarthritis Pain Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Osteoarthritis Pain Drugs Price by Type
6 Osteoarthritis Pain Drugs Market by Application
  1. 6.1 Global Osteoarthritis Pain Drugs Revenue by Application
  2. 6.1.1 Global Osteoarthritis Pain Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Osteoarthritis Pain Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Osteoarthritis Pain Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Osteoarthritis Pain Drugs Sales by Application
  6. 6.2.1 Global Osteoarthritis Pain Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Osteoarthritis Pain Drugs Sales by Application (2021-2032) & (M Dose)
  8. 6.2.3 Global Osteoarthritis Pain Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Osteoarthritis Pain Drugs Price by Application
7 Company Profiles
  1. 7.1 Pfizer
  2. 7.1.1 Pfizer Company Information
  3. 7.1.2 Pfizer Business Overview
  4. 7.1.3 Pfizer Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Pfizer Osteoarthritis Pain Drugs Product Portfolio
  6. 7.1.5 Pfizer Recent Developments
  7. 7.2 Bayer
  8. 7.2.1 Bayer Company Information
  9. 7.2.2 Bayer Business Overview
  10. 7.2.3 Bayer Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Bayer Osteoarthritis Pain Drugs Product Portfolio
  12. 7.2.5 Bayer Recent Developments
  13. 7.3 SK Chemicals
  14. 7.3.1 SK Chemicals Company Information
  15. 7.3.2 SK Chemicals Business Overview
  16. 7.3.3 SK Chemicals Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 SK Chemicals Osteoarthritis Pain Drugs Product Portfolio
  18. 7.3.5 SK Chemicals Recent Developments
  19. 7.4 GSK
  20. 7.4.1 GSK Company Information
  21. 7.4.2 GSK Business Overview
  22. 7.4.3 GSK Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 GSK Osteoarthritis Pain Drugs Product Portfolio
  24. 7.4.5 GSK Recent Developments
  25. 7.5 Sanofi
  26. 7.5.1 Sanofi Company Information
  27. 7.5.2 Sanofi Business Overview
  28. 7.5.3 Sanofi Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Sanofi Osteoarthritis Pain Drugs Product Portfolio
  30. 7.5.5 Sanofi Recent Developments
  31. 7.6 Crystal Genomics
  32. 7.6.1 Crystal Genomics Company Information
  33. 7.6.2 Crystal Genomics Business Overview
  34. 7.6.3 Crystal Genomics Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Crystal Genomics Osteoarthritis Pain Drugs Product Portfolio
  36. 7.6.5 Crystal Genomics Recent Developments
  37. 7.7 Johnson & Johnson
  38. 7.7.1 Johnson & Johnson Company Information
  39. 7.7.2 Johnson & Johnson Business Overview
  40. 7.7.3 Johnson & Johnson Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Johnson & Johnson Osteoarthritis Pain Drugs Product Portfolio
  42. 7.7.5 Johnson & Johnson Recent Developments
  43. 7.8 Sino Biopharmaceutical
  44. 7.8.1 Sino Biopharmaceutical Company Information
  45. 7.8.2 Sino Biopharmaceutical Business Overview
  46. 7.8.3 Sino Biopharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Sino Biopharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  48. 7.8.5 Sino Biopharmaceutical Recent Developments
  49. 7.9 Haohai Biological
  50. 7.9.1 Haohai Biological Company Information
  51. 7.9.2 Haohai Biological Business Overview
  52. 7.9.3 Haohai Biological Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Haohai Biological Osteoarthritis Pain Drugs Product Portfolio
  54. 7.9.5 Haohai Biological Recent Developments
  55. 7.10 Zhejiang Chengyi Pharmaceutical
  56. 7.10.1 Zhejiang Chengyi Pharmaceutical Company Information
  57. 7.10.2 Zhejiang Chengyi Pharmaceutical Business Overview
  58. 7.10.3 Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  60. 7.10.5 Zhejiang Chengyi Pharmaceutical Recent Developments
  61. 7.11 Freda
  62. 7.11.1 Freda Company Information
  63. 7.11.2 Freda Business Overview
  64. 7.11.3 Freda Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Freda Osteoarthritis Pain Drugs Product Portfolio
  66. 7.11.5 Freda Recent Developments
  67. 7.12 Bright Future
  68. 7.12.1 Bright Future Company Information
  69. 7.12.2 Bright Future Business Overview
  70. 7.12.3 Bright Future Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Bright Future Osteoarthritis Pain Drugs Product Portfolio
  72. 7.12.5 Bright Future Recent Developments
  73. 7.13 Jingfeng Pharmaceutical
  74. 7.13.1 Jingfeng Pharmaceutical Company Information
  75. 7.13.2 Jingfeng Pharmaceutical Business Overview
  76. 7.13.3 Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  78. 7.13.5 Jingfeng Pharmaceutical Recent Developments
  79. 7.14 Chugai Pharmaceutical
  80. 7.14.1 Chugai Pharmaceutical Company Information
  81. 7.14.2 Chugai Pharmaceutical Business Overview
  82. 7.14.3 Chugai Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Chugai Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  84. 7.14.5 Chugai Pharmaceutical Recent Developments
  85. 7.15 Mikasa Seiyaku
  86. 7.15.1 Mikasa Seiyaku Company Information
  87. 7.15.2 Mikasa Seiyaku Business Overview
  88. 7.15.3 Mikasa Seiyaku Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Mikasa Seiyaku Osteoarthritis Pain Drugs Product Portfolio
  90. 7.15.5 Mikasa Seiyaku Recent Developments
  91. 7.16 Taisho Pharmaceutical
  92. 7.16.1 Taisho Pharmaceutical Company Information
  93. 7.16.2 Taisho Pharmaceutical Business Overview
  94. 7.16.3 Taisho Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Taisho Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  96. 7.16.5 Taisho Pharmaceutical Recent Developments
  97. 7.17 Seikagaku Corporation
  98. 7.17.1 Seikagaku Corporation Company Information
  99. 7.17.2 Seikagaku Corporation Business Overview
  100. 7.17.3 Seikagaku Corporation Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Seikagaku Corporation Osteoarthritis Pain Drugs Product Portfolio
  102. 7.17.5 Seikagaku Corporation Recent Developments
  103. 7.18 GlaxoSmithKline
  104. 7.18.1 GlaxoSmithKline Company Information
  105. 7.18.2 GlaxoSmithKline Business Overview
  106. 7.18.3 GlaxoSmithKline Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 GlaxoSmithKline Osteoarthritis Pain Drugs Product Portfolio
  108. 7.18.5 GlaxoSmithKline Recent Developments
  109. 7.19 Eli Lilly
  110. 7.19.1 Eli Lilly Company Information
  111. 7.19.2 Eli Lilly Business Overview
  112. 7.19.3 Eli Lilly Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Eli Lilly Osteoarthritis Pain Drugs Product Portfolio
  114. 7.19.5 Eli Lilly Recent Developments
  115. 7.20 Novartis
  116. 7.20.1 Novartis Company Information
  117. 7.20.2 Novartis Business Overview
  118. 7.20.3 Novartis Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Novartis Osteoarthritis Pain Drugs Product Portfolio
  120. 7.20.5 Novartis Recent Developments
  121. 7.21 Horizon Pharma
  122. 7.21.1 Horizon Pharma Company Information
  123. 7.21.2 Horizon Pharma Business Overview
  124. 7.21.3 Horizon Pharma Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 Horizon Pharma Osteoarthritis Pain Drugs Product Portfolio
  126. 7.21.5 Horizon Pharma Recent Developments
  127. 7.22 Abbott
  128. 7.22.1 Abbott Company Information
  129. 7.22.2 Abbott Business Overview
  130. 7.22.3 Abbott Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 7.22.4 Abbott Osteoarthritis Pain Drugs Product Portfolio
  132. 7.22.5 Abbott Recent Developments
  133. 7.23 Mylan
  134. 7.23.1 Mylan Company Information
  135. 7.23.2 Mylan Business Overview
  136. 7.23.3 Mylan Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  137. 7.23.4 Mylan Osteoarthritis Pain Drugs Product Portfolio
  138. 7.23.5 Mylan Recent Developments
  139. 7.24 Daiichi Sankyo
  140. 7.24.1 Daiichi Sankyo Company Information
  141. 7.24.2 Daiichi Sankyo Business Overview
  142. 7.24.3 Daiichi Sankyo Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  143. 7.24.4 Daiichi Sankyo Osteoarthritis Pain Drugs Product Portfolio
  144. 7.24.5 Daiichi Sankyo Recent Developments
  145. 7.25 TEVA
  146. 7.25.1 TEVA Company Information
  147. 7.25.2 TEVA Business Overview
  148. 7.25.3 TEVA Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  149. 7.25.4 TEVA Osteoarthritis Pain Drugs Product Portfolio
  150. 7.25.5 TEVA Recent Developments
  151. 7.26 Almatica Pharma
  152. 7.26.1 Almatica Pharma Company Information
  153. 7.26.2 Almatica Pharma Business Overview
  154. 7.26.3 Almatica Pharma Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  155. 7.26.4 Almatica Pharma Osteoarthritis Pain Drugs Product Portfolio
  156. 7.26.5 Almatica Pharma Recent Developments
  157. 7.27 Astellas Pharma
  158. 7.27.1 Astellas Pharma Company Information
  159. 7.27.2 Astellas Pharma Business Overview
  160. 7.27.3 Astellas Pharma Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  161. 7.27.4 Astellas Pharma Osteoarthritis Pain Drugs Product Portfolio
  162. 7.27.5 Astellas Pharma Recent Developments
  163. 7.28 Tide Pharmaceutical
  164. 7.28.1 Tide Pharmaceutical Company Information
  165. 7.28.2 Tide Pharmaceutical Business Overview
  166. 7.28.3 Tide Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  167. 7.28.4 Tide Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  168. 7.28.5 Tide Pharmaceutical Recent Developments
  169. 7.29 Iroko Pharmaceuticals
  170. 7.29.1 Iroko Pharmaceuticals Company Information
  171. 7.29.2 Iroko Pharmaceuticals Business Overview
  172. 7.29.3 Iroko Pharmaceuticals Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  173. 7.29.4 Iroko Pharmaceuticals Osteoarthritis Pain Drugs Product Portfolio
  174. 7.29.5 Iroko Pharmaceuticals Recent Developments
  175. 7.30 Hengrui Pharmaceutical
  176. 7.30.1 Hengrui Pharmaceutical Company Information
  177. 7.30.2 Hengrui Pharmaceutical Business Overview
  178. 7.30.3 Hengrui Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  179. 7.30.4 Hengrui Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  180. 7.30.5 Hengrui Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America Osteoarthritis Pain Drugs Market Size by Type
  2. 8.1.1 North America Osteoarthritis Pain Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Osteoarthritis Pain Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Osteoarthritis Pain Drugs Price by Type (2021-2032)
  5. 8.2 North America Osteoarthritis Pain Drugs Market Size by Application
  6. 8.2.1 North America Osteoarthritis Pain Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Osteoarthritis Pain Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Osteoarthritis Pain Drugs Price by Application (2021-2032)
  9. 8.3 North America Osteoarthritis Pain Drugs Market Size by Country
  10. 8.3.1 North America Osteoarthritis Pain Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Osteoarthritis Pain Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Osteoarthritis Pain Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Osteoarthritis Pain Drugs Market Size by Type
  2. 9.1.1 Europe Osteoarthritis Pain Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Osteoarthritis Pain Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Osteoarthritis Pain Drugs Price by Type (2021-2032)
  5. 9.2 Europe Osteoarthritis Pain Drugs Market Size by Application
  6. 9.2.1 Europe Osteoarthritis Pain Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Osteoarthritis Pain Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Osteoarthritis Pain Drugs Price by Application (2021-2032)
  9. 9.3 Europe Osteoarthritis Pain Drugs Market Size by Country
  10. 9.3.1 Europe Osteoarthritis Pain Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Osteoarthritis Pain Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Osteoarthritis Pain Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Osteoarthritis Pain Drugs Market Size by Type
  2. 10.1.1 China Osteoarthritis Pain Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Osteoarthritis Pain Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Osteoarthritis Pain Drugs Price by Type (2021-2032)
  5. 10.2 China Osteoarthritis Pain Drugs Market Size by Application
  6. 10.2.1 China Osteoarthritis Pain Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Osteoarthritis Pain Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Osteoarthritis Pain Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Osteoarthritis Pain Drugs Market Size by Type
  2. 11.1.1 Asia Osteoarthritis Pain Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Osteoarthritis Pain Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Osteoarthritis Pain Drugs Price by Type (2021-2032)
  5. 11.2 Asia Osteoarthritis Pain Drugs Market Size by Application
  6. 11.2.1 Asia Osteoarthritis Pain Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Osteoarthritis Pain Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Osteoarthritis Pain Drugs Price by Application (2021-2032)
  9. 11.3 Asia Osteoarthritis Pain Drugs Market Size by Country
  10. 11.3.1 Asia Osteoarthritis Pain Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Osteoarthritis Pain Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Osteoarthritis Pain Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Osteoarthritis Pain Drugs Market Size by Type
  2. 12.1.1 SAMEA Osteoarthritis Pain Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Osteoarthritis Pain Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Osteoarthritis Pain Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Osteoarthritis Pain Drugs Market Size by Application
  6. 12.2.1 SAMEA Osteoarthritis Pain Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Osteoarthritis Pain Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Osteoarthritis Pain Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Osteoarthritis Pain Drugs Market Size by Country
  10. 12.3.1 SAMEA Osteoarthritis Pain Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Osteoarthritis Pain Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Osteoarthritis Pain Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Osteoarthritis Pain Drugs Value Chain Analysis
  2. 13.1.1 Osteoarthritis Pain Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Osteoarthritis Pain Drugs Production Mode & Process
  6. 13.2 Osteoarthritis Pain Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Osteoarthritis Pain Drugs Distributors
  9. 13.2.3 Osteoarthritis Pain Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst